Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**phytosterols + monacolin K** is a combination nutraceutical used primarily for lowering cholesterol levels in mildly to moderately hypercholesterolemic patients. Phytosterols inhibit intestinal absorption of cholesterol, reducing the amount of dietary cholesterol entering the bloodstream. Monacolin K, derived from red yeast rice (produced by fermentation with Monascus purpureus), is structurally identical to lovastatin and inhibits HMG-CoA reductase, blocking endogenous cholesterol synthesis in the liver. Together, these ingredients exert additive effects on lowering LDL-cholesterol and apolipoprotein B, reaching clinically significant reductions compared to either agent alone[1][2][3]. The product is often formulated as oral liquid sticks or capsules, with typical daily doses being phytosterols 800–1250 mg and monacolin K 3–10 mg.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phytosterols + monacolin K.